Posted by: Salvatore J. Zambri, founding partner
Bloomberg News (12/16, O’Reilly, Feeley) reports, “Pfizer Inc. asked a judge to order the removal of an Internet video about its menopause medicines that the company says is misleading and aimed at swaying potential jurors in future trials over the pills.” The video, called “Prempro News Segment,” was posted on YouTube.com by “plaintiffs’ lawyers who recently won more than $78 million in damages in a Pennsylvania trial over Pfizer’s Prempro hormone-replacement drug.”
At issue in that case was whether the “menopause drugs helped cause” the plaintiff’s breast cancer. In the video, “breast-cancer victims discuss their cases,” while the attorneys “accuse Wyeth of minimizing the risks of Prempro.” According to Pfizer’s lawyers, “Pennsylvania rules governing lawyer ethics prohibit lawyers from making pre-trial statements to the press that could ‘prejudice’ an upcoming case.”
About the author:
Mr. Zambri is a Past-President of the Trial Lawyers Association of Metropolitan Washington, D.C. and has been rated by Washingtonian magazine as a “Big Gun” and among the “top 1%” of all lawyers in the Washington metropolitan area. The magazine also describes him as “one of Washington’s best–most honest and effective lawyers” who specializes in personal injury matters, including product liability, medical malpractice, and automobile accident claims. Mr. Zambri has also been named a “Super Lawyer” by Super Lawyer magazine (March/April 2009)–a national publication that honors the top lawyers in America.
Mr. Zambri was sought after to publish a chapter regarding product liability litigation in Aspatore Books – a company that is touted as “the largest and most exclusive publisher of C-1 Level executives (CEO, CFO, CTO, CMO, Partner) from the world’s most respected companies and law firms.” To read Mr. Zambri’s publication, entitled “Constantly Preparing To Win”, please click here.
If you have any questions about your legal rights, please email Mr. Zambri at email@example.com or call him at 202-822-1899.